Bryan Laffitte

Genomics Institute of the Novartis Research Foundation — United States

Medicine · Health Sciences

30h-index10.0kcitations48works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cholesterol and Lipid Metabolism(19), Peroxisome Proliferator-Activated Receptors(15), Drug Transport and Resistance Mechanisms(13), Pancreatic function and diabetes(10), Cancer, Lipids, and Metabolism(7)

Publications48 total

Cross College Collaboration Of Engineering With Industrial Design
2020· 5 citedOpen Access
CCDC 2023709: Experimental Crystal Structure Determination
The Cambridge Structural Database·2020Open Access
A Dual Inhibitor of DYRK1A and GSK3β for β‐Cell Proliferation: Aminopyrazine Derivative GNF4877
ChemMedChem·2020· 16 cited
Identification of a small molecule that stimulates human β-cell proliferation and insulin secretion, and protects against cytotoxic stress in rat insulinoma cells
PLoS ONE·2020· 22 citedOpen Access
Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133
Journal of Medicinal Chemistry·2020· 74 citedOpen Access
Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis
Journal of Medicinal Chemistry·2020· 97 citedOpen Access
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non–Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers
Clinical Pharmacology in Drug Development·2019· 70 citedOpen Access
Identification of a small molecule that stimulates human β-cell proliferation and insulin secretion, and protects against cytotoxic stress in rat insulinoma cells
2019· 1 citedOpen Access
Tropifexor‐Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents
Hepatology Communications·2019· 88 citedOpen Access
Discovery of 5-(3,4-Difluorophenyl)-3-(pyrazol-4-yl)-7-azaindole (GNF3809) for β-Cell Survival in Type 1 Diabetes
ACS Omega·2019· 12 citedOpen Access
Discovery of potent and selective PPARα/δ dual antagonists and initial biological studies
Bioorganic & Medicinal Chemistry Letters·2018· 8 citedOpen Access
Abstract 374: Gpr68 Senses Blood Flow and is Essential for Vascular Physiology
Circulation Research·2018
GPR68 Senses Flow and Is Essential for Vascular Physiology
INRIA a CCSD electronic archive server·2018
LJN452 (tropifexor) attenuates steatohepatitis, inflammation, and fibrosis in dietary mouse models of nonalcoholic steatohepatitis
Journal of Hepatology·2018· 3 cited
GPR68 Senses Flow and Is Essential for Vascular Physiology
Cell·2018· 312 citedOpen Access
Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
Journal of Medicinal Chemistry·2017· 224 citedOpen Access
First-in-Human study of LMB763, a novel, orally-available farnesoid X receptor agonist that demonstrates modulation of the pharmacodynamic markers FGF19 and C4 in healthy subjects
Journal of Hepatology·2017· 3 cited
Development of LMB763, a novel, orally bioavailable, clinical farnesoid X receptor agonist for the treatment of non-alcoholic steatohepatitis and hepatobiliary disorders
Journal of Hepatology·2017· 3 cited
Inhibition of the NFAT kinases, GSK3beta and Dyrk1a, increases human beta cell proliferation and islet mass
2016· 1 cited
Pancreas‐Specific Delivery of β‐Cell Proliferating Small Molecules
ChemMedChem·2016· 8 cited
page 1 of 3Next →

Frequent Co-authors

Sean B. Joseph(16), Peter Tontonoz(14), Peter McNamara(13), Valentina Molteni(10), Weijun Shen(8), Tom Wu(7), Richard Glynne(7), David J. Mangelsdorf(6), Jon L. Collins(6), Paul V. Rucker(6), D. CHIANELLI(6), Dingjiu Bao(6), Jocelyn Zoll(6), Qihui Jin(6), Michael K. Badman(6), Peter A. Edwards(5), Damien C. Wilpitz(5), Robert Walczak(5), David C. Tully(5), Anwesh Kamireddy(5)